Giant prolactinomas in women

European Journal of Endocrinology

Volumn 170, Issue 1, 2014, Pages 31-38

  Delgrange, Etienne ^a   Raverot, Gerald ^b   Bex, Marie ^c   Burman, Pia ^d   Decoudier, Béńedicte ^e   Devuyst, France ^f   Feldt Rasmussen, Ulla ^g   Andersen, Marianne ^h   Maiter, Dominique ⁱ  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f ERASME HOSPITAL   (Belgium)

^g University of Copenhagen   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PERGOLIDE; PROLACTIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMENORRHEA; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID RHINORRHEA; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROLACTINOMA; RETROSPECTIVE STUDY; SEX RATIO; SYNDROME DELINEATION; TUMOR VOLUME; VERY ELDERLY;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMENORRHEA; ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; TUMOR BURDEN; YOUNG ADULT;

EID: 84890505939     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0503     Document Type: Article

References (37)

1. Shrivastava RK, Arginteanu MS, King WA & Post KD. Giant prolactinomas: clinical management and long-term follow-up. Journal of Neurosurgery 2002 97 299-306. (doi:10.3171/jns.2002.97.2.0299)
2. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA & Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology 2003 58 662-670. (doi:10.1046/j.1365-2265.2003.01770.x)
3. Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ & KimMS. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. Journal of Korean Medical Science 2009 24 874-878. (doi:10.3346/jkms.2009.24.5.874)
4. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534. (doi:10.1210/er.2005-9998)
5. Lundberg PO, Osterman PO &Wide L. Serum prolactin in patients with hypothalamus and pituitary disorders. Journal of Neurosurgery 1981 55 194-199. (doi:10.3171/jns.1981.55.2.0194)
6. Cole DR, Lees PD & Armitage M. A good wife, but never a mother. Journal of the Royal Society of Medicine 1995 88 176P-178P.
7. Saeki N, Nakamura M, Sunami K & Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocrine Journal 1998 45 529-537. (doi:10.1507/endocrj.45. 529)
8. Al Sifri SN & Raef H. The hook effect in prolactin immunoassays. Saudi Medical Journal 2004 25 656-659.
9. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS & Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. Journal of Neurosurgery 2006 104 54-61. (doi:10.3171/jns.2006.104.1.54)
10. Yener S, Comlekci A, Arda N, Men S & Yesil S. Misdiagnosis due to the hook effect in prolactin assay. Medical Principles and Practice 2008 17 429-431. (doi:10.1159/000141512)
11. Acharya SV, Gopal RA, Menon PS, Bandgar TR & Shah NS. Giant prolactinoma and effectiveness of medical management. Endocrine Practice 2010 16 42-46. (doi:10.4158/EP09221.OR)
12. Yang MS, Hong JW, Lee SK, Lee EJ & Kim SH. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. Journal of Neuro-Oncology 2011 104 195-204. (doi:10.1007/s11060-010-0459-3)
13. Clayton RN, Webb J, Heath DA, Dunn PJ, Rolfe EB & Hockley AD. Dramatic and rapid shrinkage of a massive prolactinoma with bromocriptine: a case report. Clinical Endocrinology 1985 22 573-581. (doi:10.1111/j.1365-2265. 1985.tb02992.x)
14. Khan EG & Howlett TA. Two macroprolactinomas presenting with neurological signs. Journal of the Royal Society of Medicine 1995 88 111P-112P.
15. Siegel RD & Lee SL. Pneumocephalus and cerebrospinal fluid rhinorrhea after bromocriptine therapy of an invasive prolactinoma: a case report and review of the literature. Endocrinologist 1996 6 148-152. (doi:10.1097/00019616- 199603000-00012)
16. Zikel OM, Atkinson JLD & Hurley DL. Prolactinoma manifesting with symptomatic hydrocephalus. Mayo Clinic Proceedings 1999 74 475-477. (doi:10.4065/74.5.475)
17. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP & Wardlaw SL. Long-term treatment of prolactin-secreting macroadenomas with pergolide. Journal of Clinical Endocrinology and Metabolism 2000 85 8-13. (doi:10REF17Z10.1210/jc.85.1.8)
18. Harzallah F, Harzallah L, Ben Brahim A, Mekaouer A & Slimane H. Macroadénome à prolactine révélé par une exophtalmie. Journal Français d'Ophtalmologie 2009 32 133e1-133e3. (doi:10.1016/j.jfo.2008.12.005)
19. Delgrange E, Daems T, Verhelst J, Abs R & Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European Journal of Endocrinology 2009 160 747-752. (doi:10.1530/EJE-09-0012)
20. Symon L, Jakubowski J & Kendall B. Surgical treatment of giant pituitary adenomas. Journal of Neurology, Neurosurgery, and Psychiatry 1979 42 973-982. (doi:10.1136/jnnp.42.11.973)
21. Shimon I, Benbassat C & Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. European Journal of Endocrinology 2007 156 225-231. (doi:10.1530/EJE-06-0646)
22. Davis JR, Sheppard MC & Heath DA. Giant invasive prolactinoma: a case report and review of nine further cases. Quarterly Journal of Medicine 1990 275 227-238.
23. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Journal of Clinical Endocrinology and Metabolism 2010 95 1708-1716. (doi:10.1210/jc.2009-1191)
24. Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107. (doi:10.1210/jc.82.7.2102)
25. Nabarro JD. Pituitary prolactinomas. Clinical Endocrinology 1982 17 129-155. (doi:10.1111/j.1365-2265.1982.tb01573.x)
26. Moraes A, Marques dos Santos Silva C, Vieira Neto L & Gadelha MR. Giant prolactinomas: the therapeutic approach. Clinical Endocrinology 2013.
27. Garcia de la Torre N, Turner HE & Wass JA. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. Pituitary 2005 8 17-23. (doi:10REF27Z10.1007/s11102-005-5081-6)
28. Delgrange E, Sassolas G, Perrin G, Jan M & Trouillas J. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochirurgica 2005 147 751-758. (doi:10.1007/s00701-005-0498-2)
29. Sarwar K, Huda M, Van de Velde V, Hopkins L, Luck S, Preston R, McGowan B, Carroll P & Powrie J. The prevalence and natural history of pituitary haemorrhage in prolactinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 2362-2367. (doi:10.1210/jc.2013-1249)
30. Cannavò S, Ferraù F, Ragonese M, Curtò L, Torre ML, Magistri M, Marchese A, Alibrandi A & Trimarchi F. Increased prevalence of acromegaly in a highly polluted area. European Journal of Endocrinology 2010 163 509-513. (doi:10.1530/EJE-10-0465)
31. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B et al. Pituitary tumors and hyperplasia in multiple neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. American Journal of Surgical Pathology 2008 32 534-543. (doi:10.1097/PAS. 0b013e31815ade45)
32. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology 2011 165 509-515. (doi:10.1530/EJE-11-0304)
33. Moger TA, Aalen OO, Halvorsen TO, Storm HH & Tretli S. Frailty modelling of testicular cancer incidence using Scandinavian data. Biostatistics 2004 5 1-14. (doi:10.1093/biostatistics/5.1.1)
34. Mindermann T & Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 1994 41 359-364. (doi:10.1111/j.1365-2265.1994.tb02557.x)
35. Backer-Grøndahl T, Moen BH & Torp SH. The histopathological spectrum of human meningiomas. International Journal of Clinical and Experimental Pathology 2012 5 231-242.
36. Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L & Gulino A. Cellular receptors for sex steroids in human pituitary adenomas. Journal of Endocrinology 1996 151 175-184. (doi:10.1677/joe.0.1510175)
37. Yarman S, Kurtulmus N & Bilge A. Optimal effective doses of cabergoline and bromocriptine and valvular lesions in men with prolactinomas. Neuroendocrinology Letters 2012 33 340-346.